Guidant

Devices & Diagnostics

BSX to pay $30M to end allegations Guidant sold defective defibrillators to Medicare

Guidant continues to prove itself as Boston Scientific’s biggest legal headache. Reuters reports Boston Scientific (BSX) has agreed to pay a $30 million settlement to bring two-year civil lawsuit, and with it allegations that Guidant knowingly sold defective defibrillators used in Medicare patients, to an end. BSX bought Guidant in 2006. Guidant sold the defibrillators, which […]

Devices & Diagnostics

Minnesota company raises $29.6 million for implantable hypertension technology

CVRx, a Minneapolis-based firm that has developed proprietary implantable technology for the treatment of high blood pressure and heart failure, has raised $29.6 million for advancing clinical trials of its Barostim Neo, as well as expanding commercial activities abroad. Johnson & Johnson Development Corp. and New Enterprise Associates, Inc. were the co-lead investors. According to […]

Devices & Diagnostics

BSX: Federal Guidant lawsuit ‘should not have a significant financial impact’

The Massachusetts-based maker of new innovative medical devices says the federal government's lawsuit over Guidant defibrillators "should not have a significant financial impact." The Justice Department filed a civil lawsuit on Thursday accusing Guidant, which Boston Scientific acquired in 2006 for $27 billion, of causing healthcare providers to file fraudulent Medicare claims.

Devices & Diagnostics

Tale of two Boston Scientifics

Earlier this week, I e-mailed the head of media relations at Boston Scientific Corp. (NYSE: BSX) on a story about a lawsuit. Not really expecting him to return my message (he didn't and never does), I cced Steve Goodyear, an all round good guy who handles media calls for the company's cardiovascular division in Maple Grove.

MedCity Influencers

Minnesota docs: Prosecute, don’t settle, over Guidant

Two Minneapolis Heart Institute doctors are opposing a $296 million plea agreement involving Boston Scientific Corp.’s (NYSE:BSX) Guidant division. Earlier this month, Boston Scientific agreed to settle charges stemming from a four-year investigation into possible criminal violations of the Federal Food, Drug, and Cosmetic Act. Under the terms of the plea, which must still be […]